Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Rising Oral Dose Study of TAK-994 in Narcolepsy (Japan Phase 2)
jRCT2080225083Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of firazorexton in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) (8 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability of TAK-994, Pharmacokinetics of TAK-994 and 1 more. Started Feb 2020; status: completed.
02
Drugs
firazorexton
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on jRCT2080225083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225083.